Pledpharma: Breakthrough beckons

Research Update

2019-02-06

11:12

The recent positive surprise over its Japanese milestone payment highlights how unwarranted investors’ negativity towards Pledpharma is, in our view. A 60% likelihood of Phase III trial success positions PledOx to become the world’s first approved treatment for oxaliplatin-induced peripheral neuropathy and to eventually achieve near-blockbuster peak sales. Against this supportive backdrop, we see even greater value in the stock now.

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.